JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.
Latest Ratings for AMRX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2021 | Goldman Sachs | Upgrades | Sell | Buy |
| Dec 2020 | Guggenheim | Upgrades | Neutral | Buy |
| Nov 2020 | SVB Leerink | Maintains | Market Perform |
